A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Trial Profile

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs Avadomide (Primary) ; CC 223 (Primary) ; Spebrutinib (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 20 Aug 2018 Planned End Date changed from 15 Dec 2019 to 30 Nov 2020.
    • 17 Jun 2018 Updated results of the expansion phase Arm D (As of January 10, 2018, n=27) presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top